BMJ1d
Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39
15 Amsterdam Rheumatology and Immunology Centre, Reade, Amsterdam, The Netherlands Objectives We sought to investigate whether genetic effects on response to TNF inhibitors (TNFi) in rheumatoid ...
BMJ1d
Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
Objectives Granulocyte-macrophage colony-stimulating factor (GM-CSF) is implicated in pathogenesis of giant cell arteritis. We evaluated the efficacy of the GM-CSF receptor antagonist mavrilimumab in ...
BMJ3d
Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Correspondence to Dr Zachary Scott Wallace, Division of Rheumatology, Allergy, and Immunology and Clinical Epidemiology Program, Mongan Institute, Department of Medicine, Massachusetts General ...
BMJ4d
Single-cell RNA-seq analysis identifies meniscus progenitors and reveals the progression of meniscus degeneration
Correspondence to Dr Zhiqi Zhang, Department of Joint Surgery, Sun Yat-sen University First Affiliated Hospital, Guangzhou 510080, China; zhzhiqi{at}mail.sysu.edu.cn; Dr Weiming Liao; ...
BMJ4d
The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide
Pathology Department, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Bruxelles, Belgium Correspondence to Professor F A Houssiau, Rheumatology Department, Cliniques ...
BMJ5d
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...
BMJ4d
Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up
3 Competence Centre for Clinical Research, Skane University Hospital, Lund, Sweden 4 Department of Nephrology and Transplantation, Skane University Hospital Malmö, Lund University, Sweden Introduction ...
BMJ6d
Risk of venous thromboembolism in ankylosing spondylitis: a general population-based study
Background Venous thromboembolism (VTE), including pulmonary embolism (PE) and deep venous thrombosis (DVT), can be life threatening. An increased frequency of VTE has been found in inflammatory ...
BMJ5d
AB0664 Life expectancy in patient with giant cell arteritis (GCA): impact of vision loss
Background and purpose Several epidemiologic studies reported increased mortality in patients with GCA, while others found that the overall survival was essentially identical to that of the general ...
BMJ1d
PTPN14 phosphatase and YAP promote TGFβ signalling in rheumatoid synoviocytes
Correspondence to Dr. Nunzio Bottini, Dept. of Medicine, University of California San Diego, MC0656, La Jolla, CA 92093, USA; nbottini{at}ucsd.edu; Professor Costantino Pitzalis, William Harvey ...
BMJ2d
POS1130 PHARMACOKINETICS AND SERUM URATE LOWERING EFFECTS OF AR882, A NOVEL, POTENT AND SELECTIVE URICOSURIC AGENT, IN PATIENTS WITH GOUT
Background: AR882 is a novel, potent and selective uric acid transporter 1 (URAT1) inhibitor in Phase 2 development for the treatment of hyperuricemia and gout. In Phase 1 healthy subject studies, ...
BMJ4d
Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups
Correspondence to Simon Rothwell, Centre for Genetics and Genomics, Arthritis Research UK, University of Manchester, Manchester M13 9PL, UK; s.rothwell{at}manchester.ac.uk Objectives Idiopathic ...